ArticleCardiovascular diabetology2025
Association of insulin resistance surrogates with disease severity and adverse outcomes in chronic thromboembolic pulmonary hypertension: a multicenter cohort study.
Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Predicting all-cause and cardiovascular mortality in hypertensive patients by combining the CHG index and its obesity indicators: a prospective cohort study with survival prediction model.Cardiovascular diabetology · 2026Article
- Association of Metabolic Score for Insulin Resistance With Resistant Hypertension and Hypertension in Obstructive Sleep Apnea.The clinical respiratory journal · 2026Article
- Uric Acid-to-Albumin Ratio as a Complementary Biomarker for In-Hospital Risk Stratification in Patients with Pulmonary Hypertension: A Retrospective Cohort Study.Journal of cardiovascular development and disease · 2026Article
- Association between a composite metabolic index and mortality in critically ill patients with pulmonary hypertension: a retrospective cohort study.Scientific reports · 2026Article
- Clinical research on pulmonary hypertension from a 2025 perspective: a narrative review.Journal of thoracic disease · 2026Review
- Association of triglyceride-glucose related indices with the incidence of venous thromboembolism: a nationwide prospective cohort study based on the UK Biobank.BMC cardiovascular disorders · 2026Article
- Association of cumulative cholesterol-HDL-glucose index with blood pressure changes and risk of new-onset hypertension in middle-aged and older adults: a cohort study.Cardiovascular diabetology · 2026Article
- Article
- Association between triglyceride glucose-body mass index and preeclampsia risk in advanced maternal age pregnant women-a retrospective cohort study.Scientific reports · 2025Article
- Associations of the Triglyceride-Glucose Index and Body Fat Composition with Blood Pressure in Children and Adolescents.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2025Article
- Review
- The Triglyceride-glucose Index Predicts Short-Term Mortality in Critically Ill Patients With Cancer-Associated Thrombosis: A Retrospective Cohort Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic thromboembolic pulmonary hypertension (CTEPH) is a severely progressive disease that leads to right heart failure and death. Previous studies have shown that diabetes and insulin resistance (IR) are closely related to pulmonary hypertension, but the role of IR in patients with CTEPH remains unexplored. In this study, we investigated the relationship between four insulin resistance indices and disease severity, hemodynamic parameters, and adverse outcomes in patients with CTEPH.
methodsWe conducted a multicenter, retrospective cohort study involving 516 patients diagnosed with CTEPH between January 2013 and December 2022. The metabolic score for IR (METS-IR), triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio, triglyceride and glucose (TyG) index, and triglyceride-glucose-body mass (TyG-BMI) index were used to quantify IR levels in patients with CTEPH. The primary endpoint events were clinical worsening. Multivariable Cox regression, restricted cubic splines, and receiver operating characteristic analyses were used to evaluate the predictive value of surrogates for IR.
resultsCompared with in low to intermediate-low risk patients, the METS-IR (36.2 ± 6.7 vs. 37.7 ± 8.7, p = 0.038) and TyG-BMI index (204.0 ± 36.2 vs. 212.6 ± 46.5, p = 0.022) were significantly increased in high to intermediate-high risk patients. METS-IR correlated with markers of disease severity, such as World Health Organization functional class, 6-minute walk distance, and N-terminal pro-brain natriuretic peptide levels. During a mean of 2.5 years' follow-up, 110 participants experienced all-cause death or worsening condition. METS-IR independently predicted clinical worsening (hazard ratio: 1.27; 95% confidence interval 1.06-1.53 per 1.0-standard deviation increment, p = 0.009) after fully adjusting for covariates. Adding METS-IR to the COMPERA 2.0 risk score significantly improved its predictive ability, reclassification and discrimination ability.
conclusionsMETS-IR is an independent predictor of clinical worsening in patients with CTEPH. It offers a convenient marker for assessing disease severity and long-term outcomes in clinical risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.